## **Core Concept**
Enfuvirtide is an HIV fusion inhibitor used in combination therapy for the treatment of HIV/AIDS. It works by blocking the fusion of viral and cellular membranes, a critical step in the HIV replication cycle. This process involves specific interactions with proteins on the viral envelope.

## **Why the Correct Answer is Right**
Enfuvirtide acts by binding to the **gp41 subunit** of the HIV envelope glycoprotein. The gp41 subunit is crucial for the fusion process as it undergoes a conformational change that facilitates the merging of the viral envelope with the host cell membrane. By binding to gp41, enfuvirtide prevents this conformational change, thereby inhibiting viral fusion and entry into the host cell.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not accurately represent the site of action for enfuvirtide. Without a specific description, we can infer that it likely refers to another part of the viral envelope or replication machinery not directly related to gp41.
- **Option B:** This option is incorrect as it also does not accurately describe the gp41 subunit or another correct site of action for enfuvirtide.
- **Option D:** This option is incorrect because it too does not correspond with the known mechanism of action of enfuvirtide, which specifically involves gp41.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that enfuvirtide is administered via injection (subcutaneously) and is used as part of a salvage regimen in patients with HIV who have developed resistance to other treatments. Its unique mechanism of action makes it valuable in combination therapy.

## **Correct Answer:** .